ライフサイエンスコーパス: uveal

1 t CAR-T cells directed against HER2 can kill uveal and cutaneous melanoma cells in vitro and in vivo.

2 clinical translation of CAR-T cells against uveal and cutaneous melanoma that do not respond to TIL

3 ermline BAP1 mutations with a propensity for uveal and cutaneous melanomas and other internal maligna

4 in approximately 83% and approximately 6% of uveal and skin melanomas, respectively.

5 als; as well as pathophysiologic features of uveal biocompatibility, capsular biocompatibility, and p

6 Of 7731 patients with posterior uveal (ciliary body and choroidal) melanoma, the AJCC tu

7 Uveal coloboma represents one of the most common congeni

8 [51.1%] and 23 men [48.9%]) and 349 with OA-uveal DLBCL (192 women [55.0%] and 157 men [45.0%]) had

9 months; 95% CI, 14.2-61.8 months) than in OA-uveal DLBCL (96.0 months; 95% CI, 67.3-124.7 months; Man

10 The 5-year survival in PVRL vs OA-uveal DLBCL differed by 17.7%, and overall survival was

11 RL was 41.4% (SE, 8.6%); among those with OA-uveal DLBCL, 59.1% (SE, 2.8%; Mantel-Cox test, P = .007)

12 For all PVRL and OA-uveal DLBCL, a Cox proportional hazards regression model

13 inal lymphoma (PVRL) and ocular adnexal (OA)-uveal DLBCL.

14 ion with external drainage for nanophthalmic uveal effusion can provide immediate and stable gain in

15 report an unusual case of non-nanophthalmic uveal effusion syndrome (UES) with histologically normal

16 Uveal effusion syndrome is a rare entity of idiopathic e

17 rst time, we report 2 cases of nanophthalmic uveal effusion syndrome managed with our technique.

18 erostomy group, eyes developed postoperative uveal effusions (P = .04).

19 ery reduces complication rates, particularly uveal effusions.

20 anterior chamber, where they caused profound uveal inflammation and release of proinflammatory cytoki

21 ent in 53 patients; 42 had massive posterior uveal invasion (>= 3 mm); 15 had concomitant peripapilla

22 Uveal lymphoma has distinctive clinical features.

23 , ciliary body, lacrimal gland, or orbit (OA-uveal lymphoma) were included.

24 The normal retinal pigment epithelium and uveal melanocytes did not stain for PAX8.

25 Bilateral diffuse uveal melanocytic proliferation (BDUMP) is a rare parane

26 al detachment, rapid cataract formation, and uveal melanocytic tumors.

27 tely half of the patients died of metastatic uveal melanoma (10-year rate, 48.5%; 95% CI, 43.0%-54.4%

28 uveal melanoma xenografts, 57 patients with uveal melanoma (17 patients whose tumors metastasized an

29 Forty patients with uveal melanoma (mean age, 57.98+/-14.75 years) were incl

30 lignancies among BAP1 mutation carriers were uveal melanoma (n = 60 [28%]), mesothelioma (n = 48 [22%

31 erapy (EPBT) for locally recurrent posterior uveal melanoma (PUM).

32 Uveal melanoma (UM) can be divided into prognostically s

33 e of genetic risk factors in the etiology of uveal melanoma (UM) has been strongly suggested, the gen

34 ound Overall survival (OS) for patients with uveal melanoma (UM) hepatic metastases is extremely poor

35 expression profile (GEP) testing segregates uveal melanoma (UM) into 2 main prognostic classes.

36 Uveal melanoma (UM) is a currently untreatable form of m

37 Uveal melanoma (UM) is a highly metastatic cancer that,

38 Human uveal melanoma (UM) is a major ocular malignant tumor wi

39 Uveal melanoma (UM) is a rare intraocular tumor that, si

40 Uveal melanoma (UM) is an aggressive tumor in which appr

41 Uveal melanoma (UM) is the most common cancer in adult e

42 Uveal melanoma (UM) is the most common intraocular tumou

43 Uveal melanoma (UM) is the most common primary intraocul

44 Uveal melanoma (UM) is the most common primary intraocul

45 (TCGA) classification has been validated for uveal melanoma (UM) prognostication.

46 istopathologic growth patterns of metastatic uveal melanoma (UM) to the liver.

47 eration (SCD) has been observed in eyes with uveal melanoma (UM), but, to our knowledge, a definitive

48 n 1 (BAP1) are associated with metastasis in uveal melanoma (UM), the deadliest adult eye cancer.

49 11) proteins, occur in about 85% of cases of uveal melanoma (UM), the most common cancer of the adult

50 describe the unique accumulation of cases of uveal melanoma (UM).

51 proteins, are initiating oncogenic events in uveal melanoma (UM).

52 ring the human eIF1A NTT are associated with uveal melanoma (UM).

53 e been described in the following 5 genes in uveal melanoma (UM): BAP1, EIF1AX, GNA11, GNAQ, and SF3B

54 aluated 48 patients with local recurrence of uveal melanoma after primary treatment with brachytherap

55 s known about the long-term risk of dying of uveal melanoma after treatment with radiotherapy.

56 52 studies, reporting on 1010 patients with uveal melanoma and 34 intraocular metastases, were eligi

57 ent selection criteria included diagnosis of uveal melanoma and adequate records to allow tumor stagi

58 ermline BAP1 mutations occur infrequently in uveal melanoma and are associated with larger tumors and

59 ntervals (95%CIs) with respect to death from uveal melanoma and death from all causes.

60 t is the most robust prognostic indicator in uveal melanoma and early studies of mostly larger tumors

61 responses were observed in one patient with uveal melanoma and four of 15 evaluable patients with RC

62 issense variants we identified are common in uveal melanoma and have been shown to constitutively act

63 between the BAP1 immunoreactivity of primary uveal melanoma and other clinicopathologic features.

64 t intraocular tumors in adults and children (uveal melanoma and retinoblastoma, respectively).

65 Clinical characteristics of uveal melanoma and the development of metastases.

66 expression with major prognostic factors for uveal melanoma and the development of metastasis.

67 Choroidal nevus is a precursor for uveal melanoma and there are no known risk factors besid

68 Recent advances in the molecular genetics of uveal melanoma are revolutionizing our understanding of

69 mber 2013 among 120 patients with metastatic uveal melanoma at 15 academic oncology centers in the Un

70 Sampling of a clinically diagnosed posterior uveal melanoma at a single site for prognostic GEP testi

71 treated with primary proton beam therapy for uveal melanoma at the oncology service at Charite-Berlin

72 lopment of a new molecular classification of uveal melanoma based on a widely available 15-gene expre

73 linical macular edema is common in eyes with uveal melanoma before and at 4 months after plaque radio

74 Quantification of the risk of developing uveal melanoma can enhance counseling regarding surveill

75 In comparison, uveal melanoma cases with BAP1 germline pathogenic varia

76 Levels of sc-Met in uveal melanoma cell cultures and in the blood serum samp

77 t was studied in the conditioned medium of 9 uveal melanoma cell lines and in the blood serum samples

78 The conditioned medium of uveal melanoma cell lines and the blood serum samples of

79 The TSN from uveal melanoma cell lines is capable of affecting the ch

80 resistance in newly characterized metastatic uveal melanoma cell lines to clinical-grade MEK inhibito

81 ARF6 with a small-molecule inhibitor reduces uveal melanoma cell proliferation and tumorigenesis in a

82 ere, in a series of experiments, using human uveal melanoma cells (MEL 270), human embryonic kidney c

83 No significant cell shearing of uveal melanoma cells occurred in vitro with 25 G, 27 G,

84 Exposure of freshly cultured uveal melanoma cells to hypoxia led to an increased expr

85 kappaB inhibitors synergistically sensitized uveal melanoma cells to PLX51107 treatment.

86 Survival of uveal melanoma cells was evaluated in vitro following ne

87 bility and for MC1R-specific cytotoxicity in uveal melanoma cells, and the lanthanum-DOTA-MC1RL analo

88 Galphaq promotes the YAP-dependent growth of uveal melanoma cells, thereby identifying YAP as a suita

89 ate that CD147 regulates MMP-2 expression in uveal melanoma cells.

90 differentially expressed in cultured primary uveal melanoma cells.

91 Compared with uveal melanoma classified as AJCC stage I, the rate of m

92 Survival of patients with uveal melanoma classified to have a bad prognosis.

93 ted variability in survival of patients with uveal melanoma classified to have a bad prognosis.

94 ic FNAB had an unequivocal primary posterior uveal melanoma clinically, while patients who underwent

95 The TSN of 1 cell line and 2 primary uveal melanoma cultures inhibited the dendritic cell mat

96 From the Wills Eye Hospital Oncology Service Uveal Melanoma Cytogenetic Database (N = 1172), 128 pati

97 every 4 months after plaque radiotherapy for uveal melanoma demonstrated OCT-evident macular edema, c

98 , whereas somatic Galpha11 mutations mediate uveal melanoma development by constitutively up-regulati

99 ) in patients undergoing prognostication for uveal melanoma does not exist.

100 ice, of healthy donors, and of patients with uveal melanoma during follow-up.

101 our patients developed nonorbital metastatic uveal melanoma during the study period.

102 astatic death in 299 patients with posterior uveal melanoma evaluated by fine-needle aspiration biops

103 Patients diagnosed with uveal melanoma from 1995 to 2016 and treated with episcl

104 ent selection criteria included diagnosis of uveal melanoma from April 1, 2001, to April 1, 2011, ade

105 with episcleral brachytherapy for posterior uveal melanoma from January 2004 to December 2014.

106 All patients with a clinical diagnosis of uveal melanoma from May 2009 to July 2013 who underwent

107 on, and assessed the effect of NPS-2143 on a uveal melanoma Galpha11 mutant.

108 The probability of uveal melanoma given that BAP1 mutation exists was deriv

109 One patient without a family history of uveal melanoma had a single nucleotide substitution in t

110 date, the role of germline BAP1 mutations in uveal melanoma has not been characterized.

111 Metastatic uveal melanoma has poor overall survival (OS) and no app

112 The treatment of uveal melanoma has seen a shift towards eye conserving t

113 n is a promising treatment for patients with uveal melanoma hepatic metastases.

114 Conditional survival estimates of uveal melanoma improve with time since primary diagnosis

115 se patients from 6 families had a history of uveal melanoma in 1 relative, and 2 patients from 2 addi

116 cause of death was metastatic disease due to uveal melanoma in 561 patients.

117 Both had a family history of uveal melanoma in at least 1 relative.

118 ons between vitamin D signaling elements and uveal melanoma in comparison to uveal tract encourage fu

119 The point prevalence of uveal melanoma in patients with the germline BAP1 pathog

120 The number with uveal melanoma in PES studies has been small.

121 ents who underwent secondary enucleation for uveal melanoma in the London Ocular Oncology Service, be

122 d, repeatable system for dividing metastatic uveal melanoma into distinct prognostic subgroups, espec

123 A diagnosis of choroidal melanoma (ie, any uveal melanoma involving the choroid).

124 Uveal melanoma is a clinically distinct and particularly

125 Uveal melanoma is a rare tumour with no established trea

126 pression of the oncoprotein c-Met in primary uveal melanoma is associated with metastatic progression

127 loss following episcleral brachytherapy for uveal melanoma is difficult to predict for individual pa

128 results challenge the belief that metastatic uveal melanoma is immunotherapy resistant and support th

129 germline BAP1 pathogenic variant given that uveal melanoma is present.

130 Uveal melanoma is the most common eye cancer in adults a

131 Uveal melanoma is the most common primary intraocular ma

132 ion regarding the long-term risk of dying of uveal melanoma may be useful to clinicians when counseli

133 Our study indicated that the uveal melanoma melanin level inversely correlated with V

134 tin 1 receptor (MC1R) is expressed in 94% of uveal melanoma metastases, and a MC1R-specific ligand (M

135 Survival of patients with uveal melanoma metastatic to the liver correlates strong

136 produced promising outcomes in patients with uveal melanoma metastatic to the liver.

137 SIRT as first-line therapy in patients with uveal melanoma metastatic to the liver.

138 ERK phosphorylation associated with ADH2 and uveal melanoma mutants was rectified by NPS-2143.

139 Patients undergoing enucleation for uveal melanoma need to be informed of the possibility of

140 Our findings implicate CYSLTR2 as a uveal melanoma oncogene and highlight the critical role

141 of certain heterotrimeric G proteins, drive uveal melanoma oncogenesis by triggering multiple downst

142 knife radiosurgery as primary treatment for uveal melanoma or uveal metastases.

143 onsecutive patients diagnosed with posterior uveal melanoma over a 5-year period who were evaluated w

144 ht the critical role of Galphaq signaling in uveal melanoma pathogenesis.

145 A committee was formed to create uveal melanoma patient-specific data fields.

146 oma specific mortality among newly diagnosed uveal melanoma patients after five years.

147 rm outcomes concerning globe preservation in uveal melanoma patients after proton beam therapy with t

148 in vivo and a subset of liver metastases of uveal melanoma patients express activated forms of ERBB2

149 atment and long-term surveillance of treated uveal melanoma patients is necessary.

150 The age at diagnosis and the gender of the uveal melanoma patients with BAP1 germline pathogenic va

151 Uveal melanoma patients with ischemic retinal detachment

152 Uveal melanoma patients with metastatic disease usually

153 but show only modest efficacy in metastatic uveal melanoma patients.

154 Patients with metastatic uveal melanoma received at least 3 vaccinations with aut

155 Of 1059 patients with uveal melanoma sampled for status of chromosomes 3, 6, a

156 We analyzed genomics data from 136 uveal melanoma samples and found a recurrent mutation in

157 of proinflammatory genes in freshly cultured uveal melanoma samples was studied in an in vitro 24-hou

158 To examine the all-cause mortality and uveal melanoma specific mortality among newly diagnosed

159 Although an accurate uveal melanoma staging system is needed to improve resea

160 Among the characteristics of uveal melanoma that are associated with a poor prognosis

161 BAP1 immunohistochemical staining of primary uveal melanoma to evaluate metastatic risk.

162 e after I-125 brachytherapy in patients with uveal melanoma treated and followed in a Spanish referra

163 dy reviewing data from patients with primary uveal melanoma treated between October 2003 and October

164 nd histology slides of patients with primary uveal melanoma treated by enucleation were reviewed.

165 We analyzed 14 patients with metastatic uveal melanoma treated with dendritic cell vaccination.

166 onic lymphocytic leukemia, breast cancer and uveal melanoma tumor samples, we show that hundreds of c

167 Severe combined immunodeficient mice bearing uveal melanoma tumors or engineered MC1R-positive and -n

168 BASE for studies reporting survival data for uveal melanoma undergoing prognostic testing with chromo

169 sc-Met levels in patients with nonmetastatic uveal melanoma vs patients with metastatic uveal melanom

170 quencing from blood samples of patients with uveal melanoma was correlated with clinical characterist

171 Two hundred fifteen patients whose primary uveal melanoma was managed in the Helsinki University Ho

172 nts aged 45 to 79 years with newly diagnosed uveal melanoma was recruited between 2002 and 2004 from

173 The cytologic characteristics of uveal melanoma were analyzed for 150 consecutive patient

174 Main prognostic factors for the death of uveal melanoma were ciliary body involvement (HR: 1.7 (9

175 l of 21 consecutive patients with metastatic uveal melanoma were enrolled between June 7, 2013, and S

176 None of the mutations associated with uveal melanoma were found.

177 A total of 6863 cases of uveal melanoma were identified.

178 tant Galpha11 proteins causing FHH2, ADH2 or uveal melanoma were transfected in CaSR-expressing HEK29

179 Indications for secondary enucleations for uveal melanoma were tumor recurrence, neovascular glauco

180 ariants in consecutive Finnish patients with uveal melanoma who come from a high-risk region for the

181 logy referral center among 507 patients with uveal melanoma who consented for collection of blood sam

182 ic variants of BAP1 in Finnish patients with uveal melanoma who live in a high-risk region for this c

183 survival in high-risk patients with primary uveal melanoma who received adjuvant sunitinib with inst

184 ce of 96 patients with clinical diagnosis of uveal melanoma who underwent prognostication at the time

185 Patients with uveal melanoma who underwent transscleral or transvitrea

186 cutive patients with a clinical diagnosis of uveal melanoma who were treated at the Cleveland Clinic

187 Variability exists in reported survival for uveal melanoma with a bad prognosis.

188 metastasis differs in patients with primary uveal melanoma with different grades of nuclear BAP1 imm

189 sion was found to be a peripapillary primary uveal melanoma with distinct non-pigmented and pigmented

190 All patients had a diagnosis of treated uveal melanoma with documented tumor control.

191 al was significantly longer in patients with uveal melanoma with high nuclear BAP1 stain (P = 0.004).

192 nes and the blood serum samples of mice with uveal melanoma xenografts contained significant levels o

193 Uveal melanoma xenografts growing in the liver in vivo a

194 d in the blood serum samples of 24 mice with uveal melanoma xenografts, 57 patients with uveal melano

195 c uveal melanoma vs patients with metastatic uveal melanoma yielded an area under the curve of 0.82 (

196 From 732 patients diagnosed with uveal melanoma, 311 were treated with brachytherapy.

197 y period 515 enucleations were performed for uveal melanoma, 99 (19%) of which were secondary enuclea

198 aluated the mechanisms of BETi resistance in uveal melanoma, a disease with little treatment options,

199 ying YAP as a suitable therapeutic target in uveal melanoma, a GNAQ/GNA11-initiated human malignancy.

200 For diagnostic biopsy of uveal melanoma, a larger-gauge needle or a 27 G vitrecto

201 eir lifetime, mostly malignant mesothelioma, uveal melanoma, and so on.

202 enase [LDH]) perform poorly in patients with uveal melanoma, and the search for new biomarkers is nee

203 Early detection of posterior uveal melanoma, at a point when the tumor is small, can

204 shed new light on the molecular genetics of uveal melanoma, delineating it as an atypical tumor of t

205 high local tumor control rates in recurrent uveal melanoma, especially if the primary therapy was tr

206 ing brachytherapy in patients with posterior uveal melanoma, given that an understanding of the recur

207 his analysis, we included 3088 patients with uveal melanoma, identified from a hospital-based cohort

208 etecting metastases in patients with primary uveal melanoma, if combined with LFT and, in case of any

209 naling pathways in the human uveal tract and uveal melanoma, including analysis of the expression of

210 ted protein-1 (BAP1) gene has been linked to uveal melanoma, mesothelioma, meningioma, renal cell car

211 mutually exclusive pattern in most cases of uveal melanoma, one of the most aggressive cancers.

212 on exists was derived from the prevalence of uveal melanoma, prevalence of germline BAP1 pathogenic v

213 s-generating study of patients with advanced uveal melanoma, selumetinib compared with chemotherapy r

214 or-associated lymphocytes, most prominent in uveal melanoma, showed positive results for PAX8.

215 BRD9 is a potent tumour suppressor in uveal melanoma, such that correcting mis-splicing of BRD

216 ntroduce the first transgenic mouse model of uveal melanoma, which develops cancers induced by expres

217 therapies are greatly needed for metastatic uveal melanoma, which has a very poor prognosis with a m

218 ilimumab demonstrates activity in metastatic uveal melanoma, with deep and sustained confirmed respon

219 ee on Cancer's 7th Edition Classification of Uveal Melanoma," published online January 2, 2015, in JA

220 mary orbital conjunctiva melanoma-like and a uveal melanoma-like group.

221 To determine the personalized rate of uveal melanoma-related metastasis on the basis of indivi

222 We report our experience with uveal melanoma-specific gene expression profile (GEP) te

223 edle aspiration biopsy for cytopathology and uveal melanoma-specific GEP testing for molecular progno

224 The 5-year uveal melanoma-specific survival probability was 82.9% (

225 a promising potential therapeutic target in uveal melanoma.

226 cinoma, mesothelioma and meningioma, but not uveal melanoma.

227 TILs) could mediate regression of metastatic uveal melanoma.

228 umour regression in patients with metastatic uveal melanoma.

229 RAB31 was a predictor of metastasis risk in uveal melanoma.

230 lps determine the diagnosis and prognosis in uveal melanoma.

231 protein-1 gene (BAP1) predispose carriers to uveal melanoma.

232 ion retinopathy and alternative therapies of uveal melanoma.

233 etected in 2 of 8 families with a history of uveal melanoma.

234 ptomatic metastases in patients with primary uveal melanoma.

235 e, 2131 deaths were the result of metastatic uveal melanoma.

236 stemic surveillance in patients with primary uveal melanoma.

237 nti-cMET monoclonal antibodies in metastatic uveal melanoma.

238 embers of this kindred reported a history of uveal melanoma.

239 r exploited as a biomarker for monitoring of uveal melanoma.

240 the initiation and metastatic progression of uveal melanoma.

241 esized to play a role in the pathogenesis of uveal melanoma.

242 cificity in the identification of metastatic uveal melanoma.

243 protein 1 gene) are frequently identified in uveal melanoma.

244 edition of the AJCCCancer Staging Manual for uveal melanoma.

245 tient-specific data fields for patients with uveal melanoma.

246 ng the standard of care in the management of uveal melanoma.

247 overall survival in patients with metastatic uveal melanoma.

248 thought to occur early in the development of uveal melanoma.

249 ars to be a prognostic factor for death from uveal melanoma.

250 individual prediction model of survival from uveal melanoma.

251 be made for or against specific therapy for uveal melanoma.

252 cancer cells as well as Galpha(q/11) mutated uveal melanoma.

253 hods in uveal tract disorders, especially in uveal melanoma.

254 ther showed that vitamin D is metabolized in uveal melanoma.

255 x of the GEP test in patients with posterior uveal melanoma.

256 of BET inhibition in patients with advanced uveal melanoma.

257 sduction axis is crucial for tumor growth in uveal melanoma.

258 DOTA-MC1RL as a novel therapy for metastatic uveal melanoma.

259 of these targeted therapies in patients with uveal melanoma.

260 led for enucleation as primary treatment for uveal melanoma.

261 A total of 1059 patients with uveal melanoma.

262 r molecular prognostication in patients with uveal melanoma; however, class 1 and class 2 test result

263 Comprehensive multiplatform analysis of 80 uveal melanomas (UM) identifies four molecularly distinc

264 tions in GNAQ or GNA11 occurs in over 80% of uveal melanomas (UMs) and activates MAPK.

265 is associated with more benign behavior for uveal melanomas (UMs) with an otherwise high risk of met

266 is an efficacious primary method of treating uveal melanomas and intraocular metastases, with reliabl

267 mutations are predominantly associated with uveal melanomas and mesotheliomas.

268 omplications of gamma knife radiosurgery for uveal melanomas and metastases.

269 ormed multi-region DNA sequencing of primary uveal melanomas and their matched metastases from 35 pat

270 Uveal melanomas are molecularly distinct from cutaneous

271 In Finland, uveal melanomas are treated centrally in the Ocular Onco

272 egate the clinical outcomes of patients with uveal melanomas or intraocular metastases treated primar

273 EER database, the median age at diagnosis of uveal melanomas was 63 (range 3-99 years) with a male-to

274 nal experience with plaque brachytherapy for uveal melanomas with a focus on local control rates, fac

275 Uveal melanomas with BAP1 mutations demonstrate sensitiv

276 iated protein-1 (BAP1) expression of primary uveal melanomas without and with metastasis, and to anal

277 D147 and MMP-2 was analyzed in 49 samples of uveal melanomas.

278 d MMP-2 were expressed in 47 (96.0 %) of the uveal melanomas.

279 ha and RORgamma in the human uveal tract and uveal melanomas.

280 Uveal metastases are ophthalmologic tumors that have his

281 und to be an effective management option for uveal metastases associated with systemic cancer.

282 The uveal metastases were treated with teletherapy (31%), ch

283 y as primary treatment for uveal melanoma or uveal metastases.

284 Of 194 patients with uveal metastasis from lung cancer, 44% did not have a hi

285 There were 194 patients with a diagnosis of uveal metastasis from lung cancer.

286 Diagnosis of uveal metastasis preceded the diagnosis of primary lung

287 year mortality from the time of detection of uveal metastasis was 54%.

288 There were 374 uveal metastatic tumors originating from primary lung ca

289 Key exclusion criteria included uveal or mucosal melanoma, previous therapy with checkpo

290 idence of primary eyelid skin, conjunctival, uveal, or remote melanoma at extraocular sites.

291 ntity of idiopathic exudative detachments of uveal tissues and retina.

292 flammatory condition in which the retina and uveal tissues become a target of autoreactive immune cel

293 encing (WGS) of 103 UM from all sites of the uveal tract (choroid, ciliary body, iris).

294 he vitamin D signaling pathways in the human uveal tract and uveal melanoma, including analysis of th

295 24A1, and RORalpha and RORgamma in the human uveal tract and uveal melanomas.

296 of new diagnostic and therapeutic methods in uveal tract disorders, especially in uveal melanoma.

297 nd tissues, including the iris region of the uveal tract during anterior uveitis.

298 elements and uveal melanoma in comparison to uveal tract encourage future clinical research with larg

299 nalysis supported a diagnosis of extraocular uveal tumor spread rather than a primary conjunctival tu

300 , all 3 patients demonstrated a reduction in uveal tumor volumes.